106 related articles for article (PubMed ID: 8112047)
1. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.
Jones RN; Zurenko GE
Diagn Microbiol Infect Dis; 1993; 17(4):313-6. PubMed ID: 8112047
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of Neisseria gonorrhoeae to cefpodoxime: determination of MICs and disk diffusion zone diameters.
Fekete T; Woodwell J; Cundy KR
Antimicrob Agents Chemother; 1991 Mar; 35(3):497-9. PubMed ID: 1903910
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.
Knapp CC; Sierra-Madero J; Washington JA
Antimicrob Agents Chemother; 1988 Dec; 32(12):1896-8. PubMed ID: 3245701
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity of 173 Sydney isolates of Neisseria gonorrhoeae to cefpodoxime and other antibiotics used to treat gonorrhea.
Tapsall JW; Phillips EA
Pathology; 1995 Jan; 27(1):64-6. PubMed ID: 7603756
[TBL] [Abstract][Full Text] [Related]
5. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
Wallrauch-Schwarz C; Milatovic D; Braveny I
Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
[TBL] [Abstract][Full Text] [Related]
6. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
Knothe H; Shah PM; Eckardt O
Infection; 1991; 19(5):370-6. PubMed ID: 1800379
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.
Wiedemann B; Luhmer E; Zühlsdorf MT
Infection; 1991; 19(5):363-9. PubMed ID: 1800378
[TBL] [Abstract][Full Text] [Related]
8. [In vitro antibacterial activity of RU 51746 (sodium salt of cefpodoxime). Results of a multicenter study].
Soussy CJ; Le Van Thoi J; Kitzis MD; Chanal C; Mounier M; Derlot E; Vergnaud M
Pathol Biol (Paris); 1990 May; 38(5):336-42. PubMed ID: 2195445
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Bauernfeind A; Jungwirth R
Infection; 1991; 19(5):353-62. PubMed ID: 1800377
[TBL] [Abstract][Full Text] [Related]
10. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.
Schaadt RD; Yagi BH; Zurenko GE
Antimicrob Agents Chemother; 1990 Feb; 34(2):371-2. PubMed ID: 2109583
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
[TBL] [Abstract][Full Text] [Related]
13. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
Abe T; Fukuoka T; Sato Y; Ito K; Sei M
Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.
Holt HA; Bywater MJ; Reeves DS
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():7-12. PubMed ID: 2292533
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries.
Schito GC; Georgopoulos A; Prieto J
J Antimicrob Chemother; 2002 Jul; 50 Suppl():7-11. PubMed ID: 12077154
[TBL] [Abstract][Full Text] [Related]
16. Emergence of decreased susceptibility to extended-spectrum cephalosporins in Neisseria gonorrhoeae in India.
Sood S; Mahajan N; Verma R; Kar HK; Sharma VK
Natl Med J India; 2013; 26(1):26-8. PubMed ID: 24066990
[TBL] [Abstract][Full Text] [Related]
17. Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks.
Jones RN
J Clin Microbiol; 1994 Apr; 32(4):1104-6. PubMed ID: 8027323
[TBL] [Abstract][Full Text] [Related]
18. Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes.
Limnios A; Tapsall J; Kahlmeter J; Hogan T; Ray S; Lam A; Unemo M
APMIS; 2011 Jun; 119(6):356-63. PubMed ID: 21569093
[TBL] [Abstract][Full Text] [Related]
19. Microbiological evaluation of cefpodoxime proxetil.
Wiedemann B; Luhmer E; Zühlsdorf MT
Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
[TBL] [Abstract][Full Text] [Related]
20. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
